Bridgeway Capital Management LLC cut its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 45.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 128,400 shares of the company's stock after selling 107,200 shares during the period. Bridgeway Capital Management LLC owned approximately 0.23% of Design Therapeutics worth $792,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Invesco Ltd. acquired a new position in Design Therapeutics in the fourth quarter valued at about $71,000. China Universal Asset Management Co. Ltd. bought a new stake in Design Therapeutics during the fourth quarter worth about $74,000. Kennedy Capital Management LLC bought a new stake in Design Therapeutics during the fourth quarter worth about $88,000. Intech Investment Management LLC bought a new stake in Design Therapeutics during the fourth quarter worth about $109,000. Finally, Wells Fargo & Company MN raised its holdings in Design Therapeutics by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 18,428 shares of the company's stock worth $114,000 after acquiring an additional 4,013 shares in the last quarter. 56.64% of the stock is owned by institutional investors and hedge funds.
Design Therapeutics Stock Performance
DSGN opened at $3.49 on Monday. Design Therapeutics, Inc. has a 52-week low of $2.60 and a 52-week high of $7.77. The firm has a market capitalization of $198.12 million, a PE ratio of -4.11 and a beta of 1.77. The business's 50-day simple moving average is $4.04 and its 200 day simple moving average is $4.95.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). On average, research analysts forecast that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.
Design Therapeutics Profile
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Read More
Want to see what other hedge funds are holding DSGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
